Vivid imaging

Investors in ImaginAb Inc.'s $21 million series B round expect its lead agent will provide greater specificity and sensitivity in prostate cancer detection than CT or bone scans - and do so earlier in the course of disease.

Existing investor Merieux Developpement led last week's round, with participation from fellow existing investors Novartis Venture Funds, Cycad Group and Nextech Invest...